Takeda’s gene editing partner is snapped up for $250M cash as sector continues to heat up

Looking to make genome editing its “fourth pillar” of operations, Japan’s AnGes is buying out Takeda-partnered EmendoBio for $250 million — and with it, technology designed to push past the current limitations of CRISPR gene editing.